Literature DB >> 12801448

Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes.

Debabrata Mukherjee1, Kim A Eagle.   

Abstract

Unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI) refer to a spectrum of acute severe cardiac disorders characterized by myocardial oxygen demand and supply mismatch, caused by atherosclerotic coronary artery disease. Patients presenting with acute coronary syndromes represent a major medical problem, accounting for 2.5 million hospitalizations and 500000 deaths annually in the United States alone. Of these, 1.5 million have a final diagnosis of UA, and myocardial infarction (ST-segment and non-ST-segment elevation) accounts for the remaining 1 million. The management of UA/NSTEMI presents a challenge to the cardiologist because treatment strategies continue to evolve. A number of trials have now assessed the safety and efficacy of early revascularization strategies in the treatment of patients with UA/NSTEMI, whereas others have focused on pharmacologic adjunctive therapy. An optimal single strategy encompassing most patients' needs is not clear. This review focuses on the revised American College of Cardiology/American Heart Association guidelines for the management of patients presenting with UA/NSTEMI.

Entities:  

Mesh:

Year:  2003        PMID: 12801448     DOI: 10.1007/s11886-003-0065-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  21 in total

Review 1.  Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

2.  When increased therapeutic benefit comes at increased cost.

Authors:  Alastair J J Wood
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

3.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

4.  Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.

Authors:  H D Aronow; E J Topol; M T Roe; P L Houghtaling; K E Wolski; A M Lincoff; R A Harrington; R M Califf; E M Ohman; N S Kleiman; M Keltai; R G Wilcox; A Vahanian; P W Armstrong; M S Lauer
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

5.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

Authors:  E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

6.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

Review 7.  Bivalirudin: a review of its potential place in the management of acute coronary syndromes.

Authors:  Christopher I Carswell; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.

Authors:  E M Antman; M Cohen; D Radley; C McCabe; J Rush; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

9.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Authors:  Jean-Michel Gaspoz; Pamela G Coxson; Paula A Goldman; Lawrence W Williams; Karen M Kuntz; M G Myriam Hunink; Lee Goldman
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

10.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.

Authors: 
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

View more
  1 in total

1.  In spite of good intentions: patients' perspectives on problematic social support interactions.

Authors:  Carla Boutin-Foster
Journal:  Health Qual Life Outcomes       Date:  2005-09-05       Impact factor: 3.186

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.